Reducing Your Risk of Shingles
]]>Main Page]]> | ]]>Risk Factors]]> | ]]>Symptoms]]> | ]]>Diagnosis]]> | ]]>Treatment]]> | ]]>Screening]]> | Reducing Your Risk | ]]>Talking to Your Doctor]]> | ]]>Living With Shingles]]> | ]]>Resource Guide]]>
A new ]]>vaccine]]> , Zostavax, has been approved by the FDA for usage in the prevention of shingles in those 60 years of age and older. In clinical trials, it reduced the risk of developing shingles by about 50%. Persons with a history of anaphylaxis (a type of a very bad allergic reaction) to neomycin should not receive this vaccine. In addition, avoiding undue stress and fatigue may theoretically help prevent an outbreak.
The American Academy of Dermatology website. Available at: http://www.aad.org/default.htm . Accessed February 21, 2006.
Merck website. Available at: http://www.merck.com . Accessed February 15, 2007.
National Institute of Neurological Disorders and Stroke website. Available at: http://www.ninds.nih.gov/ . Accessed February 21, 2006.
Stankus SJ, Dlugopolski M, Packer D. Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician . 2000;61(8). Available at: http://www.aafp.org/afp/20000415/2437.html.
Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol . 2007 Dec;57(6 Suppl):S136-42. Review.
Last reviewed November 2008 by ]]>Ross Zeltser, MD, FAAD]]>
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2007 EBSCO Publishing All rights reserved.